Harish Shantharam
Keine laufenden Positionen mehr
Profil
Harish Shantharam is currently the Chief Financial Officer at UCLA Anderson School of Management.
Previously, he served as the Chief Financial & Accounting Officer at CymaBay Therapeutics, Inc. from 2023 to 2024.
Prior to that, he was the Vice President-Global Commercial Finance at Gilead Sciences, Inc. from 2011 to 2022.
He also held the position of Head-Business Development at Amgen, Inc. from 2004 to 2011.
Mr. Shantharam holds a graduate degree from The University of Texas at Arlington and an MBA from UCLA Anderson School of Management.
Ehemalige bekannte Positionen von Harish Shantharam
| Unternehmen | Position | Ende |
|---|---|---|
| CYMABAY THERAPEUTICS, INC. | Finanzdirektor/CFO | 22.03.2024 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.05.2022 |
| AMGEN INC. | Corporate Officer/Principal | 01.11.2011 |
Ausbildung von Harish Shantharam
| UCLA Anderson School of Management | Masters Business Admin |
| The University of Texas at Arlington | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
